Will Lazard’s (LAZ) New Sector Leaders Strengthen Its Competitive Edge in Advisory Services?

• In late September 2025, Lazard, Inc. announced two major executive appointments: Cyrille Cotte as Managing Director and Head of Insurance for its European Financial Institutions Group, and Dr. Geoffrey Porges as Managing Director in the Healthcare Advisory Group.
• The addition of these highly experienced leaders highlights Lazard’s intent to bolster its advisory capabilities in both the insurance and healthcare sectors, reflecting a focused enhancement of its sector expertise in key markets.
• We’ll explore how the arrival of Cyrille Cotte, with his extensive insurance sector experience, could impact Lazard’s investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Lazard Investment Narrative Recap

For shareholders in Lazard, Inc., the core belief rests on the firm’s ability to leverage its diversified financial advisory and asset management services across regions, while managing the near-term risk of rising operating expenses from recent expansions and high-profile hires. The appointment of Cyrille Cotte as Head of Insurance for the European FIG is unlikely to materially affect Lazard’s most important short-term catalyst, the realization of revenue from recent client partnership initiatives, though it could contribute to sector expertise over time.

Among recent announcements, Lazard’s expanded alliance with Arini Capital Management to broaden debt advisory services across EMEA closely aligns with the company’s goals to build its financial advisory backlog and grow revenue streams. This move complements the hiring of experienced leaders, adding further weight to Lazard’s plans for deeper reach in targeted markets and reinforcing the relevance of new appointments in executing these ambitions.

By contrast, the risk that newly elevated expenses could outpace the near-term realization of advisory revenues is something investors should keep in mind as...

Read the full narrative on Lazard (it's free!)

Lazard's narrative projects $4.2 billion revenue and $620.0 million earnings by 2028. This requires 11.3% yearly revenue growth and a $317.5 million earnings increase from $302.5 million today.

Uncover how Lazard's forecasts yield a $61.00 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Fair value estimates for Lazard from four Simply Wall St Community members range from US$47 to US$70 per share, reflecting a wide span of expectations. As investors weigh these community viewpoints, the potential impact of higher costs from Lazard’s ongoing expansion remains an important factor shaping the company’s near-term results.

Explore 4 other fair value estimates on Lazard - why the stock might be worth 10% less than the current price!

Build Your Own Lazard Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Lazard research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Lazard research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lazard's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com